MedTrace Logo

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

NCT06246123 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2040

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.

Conditions

  • Arthritis, Rheumatoid
  • Colitis, Ulcerative

Interventions

OTHER

Non-interventional

No intervention will be administered.

Sponsors & Collaborators

  • Eisai Korea Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-27
Primary Completion
2027-07-30
Completion
2027-07-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06246123 on ClinicalTrials.gov